title: Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants?
abstract: Venous thromboembolism (VTE) is a frequent complication of gastrointestinal cancers that increases morbidity and may impact mortality. Low-molecular-weight heparins (LMWHs) and vitamin K antagonists (VKAs) are standard anticoagulation options for the ambulatory gastrointestinal cancer patient with VTE, but both of these agents are challenging to use for various reasons. Novel oral anticoagulants (NOAs) are new, orally available anticoagulants designed to be easier to administer with more reliable pharmacokinetics that eliminate the need for frequent monitoring of various laboratory parameters. This paper reviews the existing efficacy and safety data for the use of NOAs dabigatran etexilate, rivaroxaban, and apixaban and discusses the potential role of these agents in the management of gastrointestinal cancer-related VTE.
authors.affiliation: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Medical Center, M365 Starling Loving Hall, 410 W 10th Avenue, Columbus, OH 43210, USA.
authors.forename: Ludmila Katherine
authors.initials: LK
authors.lastname: Martin
authors.forename: Tanios
authors.initials: T
authors.lastname: Bekaii-Saab